Ionic current passes through the nanopore because a constant voltage is applied across the membrane, where the trans side is positively charged. Each channel associates with a separate electrode in the sensor chip and is controlled and measured individually by the application-specific integration circuit (ASIC). The wells are inserted into an electrically resistant polymer membrane supported by an array of microscaffolds connected to a sensor chip. In addition to controlling translocation speed, the motor protein has helicase activity, enabling double-stranded DNA or RNA–DNA duplexes to be unwound into single-stranded molecules that pass through the nanopore.Ī MinION flow cell contains 512 channels with 4 nanopores in each channel, for a total of 2,048 nanopores used to sequence DNA or RNA. Changes in the ionic current during translocation correspond to the nucleotide sequence present in the sensing region and are decoded using computational algorithms, allowing real-time sequencing of single molecules. Translocation speed is controlled by a motor protein that ratchets the nucleic acid molecule through the nanopore in a step-wise manner. In an electrolytic solution, a constant voltage is applied to produce an ionic current through the nanopore such that negatively charged single-stranded DNA or RNA molecules are driven through the nanopore from the negatively charged ‘ cis’ side to the positively charged ‘ trans’ side. The technology relies on a nanoscale protein pore, or ‘nanopore’, that serves as a biosensor and is embedded in an electrically resistant polymer membrane 1, 3 (Fig. doi:10.1038/nbt.2777 19 January 2014).Nanopore sequencing technology and its applications in basic and applied research have undergone substantial growth since Oxford Nanopore Technologies (ONT) provided the first nanopore sequencer, MinION, in 2014 (refs. It is encouraging that some efforts to develop such standards and repositories are under way ( Nat. Shared repositories with the capability to host properly annotated standardized data from different individuals will enable these large-scale studies. As such, studies intended to identify rare receptors or antibodies will require samples and data from more people than could reasonably be expected to be generated in one laboratory. If the antibody repertoires of two healthy people and two lupus patients were sequenced, as a result of the randomness mentioned above the culprit antibody would be obscured among a sea of other antibodies found in the sick but not the healthy people just as many differences might be seen between the two sick people. Consider a study aimed at identifying which autoantibodies exacerbate human lupus. The extent of heterogeneity in the human immune system means that enabling interlaboratory data sharing will be essential. Tackling human studies thus requires a quantum leap in our technological and computational sophistication. Humans are outbred-and therefore express unknown combinations of human leukocyte antigen (HLA) molecules-and are generally kept outside pathogen-free facilities as a result any group of individuals contains unknown varieties of T cells specific for unknown varieties of viral peptide-HLA complexes. Take that study into humans, and whole new dimensions of genetic and environmental complexity follow. One can take a group of animals in a pathogen-free facility and, after infecting them with a particular virus, simply track the phenotype of T cells expressing a T cell receptor (TCR) known to be specific for a particular virus epitope presented by a major histocompatibility (MHC) molecule known to be expressed in that mouse strain. One of the most formidable obstacles facing research into the human immune system is its much greater interindividual and intraindividual diversity compared with that of inbred mice.
0 kommentar(er)
